Novo Nordisk Acquires Cardior for $1.1 Billion to Expand Cardiovascular Portfolio
Novo Nordisk is set to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion in a move to strengthen its presence in cardiovascular disease, following the recent label expansion of its obesity drug Wegovy to include the reduction of cardiovascular events. This acquisition marks a strategic shift for Novo, which had previously focused on obesity-related acquisitions.